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under the CC BY-NC-ND license (http:Abstract Narrow band imaging (NBI) is a newly developed technology aiming to provide addi-
tional endoscopic information for patients with bladder cancer. This review focuses on the
diagnostic accuracy and treatment outcome using NBI cystoscopy for the treatment of non-
muscle invasive bladder cancer. Current results showed improved sensitivity of NBI cystoscopy
compared to conventional white light cystoscopy, although lower specificity and increased
false-positive results were reported using NBI cystoscopy. The treatment outcome using NBI
technology in transurethral resection of bladder tumor had a positive impact while decreased
number of residual tumors and tumor recurrence at follow-up were reported. In the future, the
application of NBI technology might refine the treatment and follow-up protocol in patients
with non-muscle invasive bladder cancer. However, this large scale prospective studies are
required to confirm the real cost-effectiveness of this new technology.
ª 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Bladder cancer is the second most common genitourinary
cancer and the fifth most common cancer in the United
States with an estimated 74,690 new cases in 2014, while
the median age at diagnosis was 73 years old [1]. The
incidence of bladder cancer is 4 times higher in men than in
women. Approximately 80% of bladder cancer was initiallyl.com (A.W. Chiu).
of Second Military Medical
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//creativecommons.org/licenses/diagnosed to be non-muscle invasive bladder cancer [2].
The standard care for non-muscle invasive bladder cancer
(pTa, pT1, carcinoma in situ) is endoscopic evaluation and
complete tumor resection [2]. However, the high recur-
rence rate and possibility for stage and grade progression in
non-muscle invasive bladder cancer warrant a life-long
surveillance. Surveillance includes screening for urine
cytology and endoscopic examination on a regular basis [3].
Since the follow-up of non-muscle invasive bladder cancer
depends mainly on accurate endoscopic evaluation, urolo-
gists are looking forward to have an ideal cystoscopy for
the surveillance of non-muscle invasive bladder cancer. The
ideal endoscopic image should be highly sensitive for
cancer detection, clear identification between benignion and hosting by Elsevier B.V. Ltd. This is an open access article
by-nc-nd/4.0/).
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characteristically. Traditionally, white light cystoscopy is
the cornerstone for evaluation of the lower urinary tract for
more than a century and serves as the most cost-effective
method to diagnose and detect the recurrence of bladder
cancer [2]. However, it is difficult to detect small bladder
cancer, such as small papillary tumors or carcinoma in situ
using white light cystoscopy, which might be related to high
recurrence rate after endoscopic resection (approximately
50%e90%) [4,5]. It is reported that up to half of patients
with high grade pTa or pT1 disease might be under staged at
first transurethral resection of bladder tumor [6], requiring
a second look transurethral resection to evaluate the
resected area during previous operation and trying to
resect all suspected lesions to allow more accurate diag-
nosis and treatment protocol selection [7]. In order to
facilitate the limitation of white light cystoscopy, some
novel imaging techniques are developed to improve the
detection of bladder cancer, such as narrow band imaging
(NBI), photodynamic diagnosis and Storz Professional
Imaging Enhancement System [8]. NBI is an optic
enhancement technique which filters the white light into
two different bandwidths, including blue (415 nm) and
green (540 nm) spectrum. In the NBI mode, the light is
strongly absorbed by hemoglobin and only penetrates the
tissue superficially, which increases the identification of
small capillaries and superficial tissue structures [9e11].
Since bladder tumors are vascular abundant structures,
the tumors could appear in brown or green color against a
white background under NBI scenario [12]. NBI technique
has become a hot topic in recent years [13e17]. The aim of
this review is to describe the outcome of diagnosis and
treatment using NBI technology for the management of
non-muscle invasive bladder cancer.2. Diagnosis of bladder cancer
Traditionally, white light cystoscopy is the gold standard for
the diagnosis of bladder cancer. However, the limitation of
white light cystoscopy to detect small bladder tumors and
carcinoma in situ resulted in the continuous investigation of
novel imaging techniques in the past decade [8,12]. In
2008, the first published study suggested that improved
detection rate of recurrent bladder cancer in NBI cystos-
copy [12]. A total of 29 patients with recurrent non-muscle
invasive bladder cancer were enrolled in this study. An
additional 41% detection rate was found in NBI cystoscopy
as compared to conventional white light cystoscopy. The
authors concluded that NBI cystoscopy is highly valuable in
the detection of both new and recurrent non-muscle inva-
sive bladder cancer and a further investigation is warranted
in more patients. In the same year, Herr and Donat [18]
reported the outcome of NBI technology for the diagnosis
of non-muscle invasive bladder cancer. A total of 427 pa-
tients were enrolled into this study while 103 patients had
tumor recurrence. The overall recurrence rate was 24.1%.
The detection rate of recurrent bladder tumor was 87.4% in
white light cystoscopy and 100% in NBI cystoscopy. The
additional detection rate was 12.6% found only in NBI
cystoscopy. The average number of recurrent tumors
detected by white light cystoscopy was 2.3 while 3.4 weredetected by NBI cystoscopy. In 2010, Tatsugami et al. [14]
reported a prospective controlled study evaluating the ef-
ficacy of NBI cystoscopy for the detection of non-muscle
invasive bladder cancer. A total of 104 patients were
enrolled into this study. A total of 313 biopsies were taken
for pathological examination. The incidence of malignancy
identified only by NBI cystoscopy was 55.7%. In 26.9% of
patients, bladder tumors were only identified by NBI
cystoscopy. The authors concluded that NBI cystoscopy is a
simple and effective method for identification of non-
muscle invasive bladder tumors. In 2012, Zheng et al. [19]
reported the clinical effective of NBI cystoscopy
compared to white light cystoscopy in patients with bladder
cancer. A total of 1022 patients were enrolled in this meta-
analysis. The pooled sensitivity and specificity of NBI
cystoscopy was 0.94 and 0.85 compared to 0.85 and 0.87 for
white light cystoscopy, respectively. The pooled sensitivity
and specificity for the diagnosis of carcinoma in situ was
0.93 and 0.77 for NBI cystoscopy. The odds ratio was 4.55 of
NBI cystoscopy compared to white light cystoscopy. The
authors concluded that NBI cystoscopy can provide higher
diagnostic precision of non-muscle invasive bladder cancer
than white light cystoscopy. In 2013, Li et al. [20] reported
a systemic review and meta-analysis on the diagnostic rate
using NBI technology in the diagnosis of non-muscle invasive
bladder cancer. A total of seven studies including 1040
patients were reviewed while 601 patients with 1476 tu-
mors were enrolled in this meta-analysis. The overall
recurrence rate was 58.8%. An additional 17% of patients
and 24% of tumors were detected using NBI cystoscopy. An
additional 28% of carcinoma in situ was detected using NBI
cystoscopy. The false-positive rate of cystoscopic biopsy
revealed comparable results using either white light
cystoscopy or NBI cystoscopy. The authors concluded that
NBI cystoscopy might serve as an alternative diagnostic
technique for non-muscle invasive bladder cancer. In 2015,
Ye et al. [21] reported a prospective randomized and multi-
center study evaluating the role of NBI and white light
cystoscopy in detecting non-muscle invasive bladder can-
cer. A total of 384 patients were enrolled into this study and
the incidence of non-muscle invasive bladder cancer was
20.3%. The sensitivity of NBI cystoscopy was 97.7% and
66.7% of white light cystoscopy. The authors concluded that
NBI cystoscopy has a high sensitivity to detect and superior
detection rate for the diagnosis of non-muscle invasive
bladder cancer than white light cystoscopy. Although NBI
cystoscopy has a higher detection rate for non-muscle
invasive bladder cancer, it is also reported that the false
positive findings are common following intravesical instil-
lation of chemotherapeutic agents or other inflammatory
condition, with the rates ranging from 32% to 36% [18,22].
In 2010, Herr [22] reported the preliminary results using NBI
cystoscopy to evaluate the response following bacillie
CalmetteeGuerin therapy. A total of 61 patients were
evaluated in this study while the overall recurrence rate
was 36% (22/61). NBI cystoscopy could correctly detect
tumors in 21 patients and only one patient with tumors
had negative findings under NBI cystoscopy. The author
concluded that NBI cystoscopy could provide better results
in patients who had suspected residual tumors following
bacillie CalmetteeGuerin therapy. In 2016, Song et al. [23]
reported the results of NBI cystoscopy early after
128 T.Y. Hsueh, A.W. Chiuintravesical instillation of chemotherapeutic agents. The
data revealed that similar sensitivity between NBI cystos-
copy and white light cystoscopy (100% vs. 94.1%), but a
significant lower specificity was found in NBI cystoscopy
compared to white light cystoscopy (50% vs. 86.9%). The
author concluded that NBI cystoscopy might result in un-
necessary biopsies for the evaluation of recurrence early
after intravesical instillation of chemotherapeutic agents.
Although the sensitivity of NBI cystoscopy shows better
results compared to white light cystoscopy, the low speci-
ficity (0.5e0.85) deserves further investigation regarding
the accuracy rate of NBI cystoscopy in the diagnosis of
bladder cancer [18e24].
3. Treatment of bladder cancer
The cornerstone management of non-muscle invasive
bladder cancer is the transurethral resection of bladder
tumor (TUR-BT) [4,5]. Since NBI cystoscopy could improve
the detection rate of bladder tumors in patients with newly
diagnosed or recurrent bladder cancer, it is reasonable to
evaluate the therapeutic outcomes in NBI assisted TUR-BT
[25e31]. In 2010, Naselli et al. [25] reported the treat-
ment outcome in patients received white light TUR-BT
followed by NBI TUR-BT. A total of 47 patients were
enrolled into this study. The detection rate of tumor
recurrence using white light TUR-BT was 21.3% (10/47)
while 34.0% (16/47) in those received NBI TUR-BT. The
authors concluded that NBI biopsies at the end of white
light TUR-BT might enhance the identification of missed
high grade residual or recurrent urothelial carcinoma of
urinary bladder. In 2011, Cauberg et al. [26] reported the
treatment outcome comparing white light TUR-BT and NBI
TUR-BT in a matched cohort study. A total of 160 patients
were retrospectively collected while 40 patients received
NBI TUR-BT and 120 patients received white light TUR-BT.
The data revealed the recurrence rate at first follow-up
cystoscopy (3 months after transurethral resection) was
30.5% following white light TUR-BT and 15.0% following NBI
TURBT. The odd ratio was 2.7 in patients received white
light TUR-BT. In 2012, a randomized controlled trial was
conducted by Naselli et al. [27] to assess the recurrence
rate of non-muscle invasive bladder cancer after NBI TUR-
BT. A total of 148 patients were randomized into received
either white light TUR-BT (72 cases) and NBI TUR-BT
(76 cases). The overall detection rate of non-muscle inva-
sive bladder cancer was 1.36 per person in white light TUR-
BT group and 1.55 per person in the NBI TUR-BT group,
respectively. The incidence of false-positive findings was
28% in the NBI TUR-BT group and 21% in the white light TUR-
BT group, respectively. The 1-year recurrence risk was
32.9% in the NBI TUR-BT group and 51.4% in the white
light TUR-BT group. The authors concluded that TUR-BT
performed under NBI technology could reduce the recur-
rence risk by at least 10% at the first year. In 2015, Koba-
take et al. [28] reported the advantage of NBI TUR-BT for
the management of non-muscle invasive bladder cancer. A
total of 135 patients with non-muscle invasive bladder
cancer were enrolled into this study. All patients did not
receive additional postoperative treatment and were
followed up for more than 1 year. The sensitivity is 95% inthe NBI TUR-BT group compared to 70% in the white light
TUR-BT group. The specificity was 77.2% in the NBI TURBT
group compared to 89.7% in the white light TUR-BT group.
The 3-month recurrence rate was 3.5% in the NBI TUR-BT
group compared to 3.8% in the white light TUR-BT group.
The 1-year recurrence rate was 21.1% in the NBI TUR-BT
group compared to 39.7% in the white light TUR-BT group.
The authors concluded that NBI TUR-BT was more advan-
tageous than white light TUR-BT for patients with non-
muscle invasive bladder cancer. Although treatment out-
comes are more favorable in patients with non-muscle
invasive bladder cancer received NBI TUR-BT, the vari-
ability between different urologists and lack of standard-
ized consensus for tumor discrimination under NBI might
limit the future perspectives in NBI TUR-BT [15,25].
4. Cost-effectiveness of NBI technology
The application of NBI technology in the diagnosis and
treatment of non-muscle invasive bladder cancer in the
past decade shows a promising result compared to con-
ventional white light technology. However, the cost-effec-
tiveness of this novel technology should be concerned
during daily clinical practice although limited data are
available from world literature. NBI technology is marketed
by Olympus as an additional function of the current
endoscopic facilities. The cost of one complete set of
Olympus endoscopic tower is around 60,000e90,000 USD
including the light source, video processor and one flexible
cystoscopy. It is reported that about 230e500 USD will be
saved per year based on the decreased disease recurrence,
although the cost of pathological analysis, additional
operative time and possible patient factors do not include
in total health care utilization [8]. The real cost-effec-
tiveness of NBI technology compared to conventional
white light technology in the diagnosis and treatment of
non-muscle invasive bladder cancer deserves further
investigation in the near future.
5. Conclusion
NBI technology facilitates the diagnosis and treatment of
non-muscle invasive bladder cancer. More large-scale,
randomized trials are needed to evaluate the diagnostic
and treatment accuracy of NBI technology and the possi-
bility to redefine the follow-up protocol in patients with
non-muscle invasive bladder cancer.Conflicts of interest
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